Meeting
2018 ASCO Annual Meeting
Preliminary toxicity data from the combination of pembrolizumab and definitive-dose radiotherapy for locally advanced head and neck cancer with contraindication to cisplatin therapy.
Authors
Jared Weiss
University of North Carolina Hospitals, Chapel Hill, NC
Jared Weiss , Jessica Ruth Bauman , Allison Mary Deal , Siddharth Sheth , Bhishamjit S. Chera , Colette Shen , Chris Hilliard , Tanguy Y. Seiwert , Ranee Mehra , Juneko E. Grilley-Olson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02609503
Citation
J Clin Oncol 36, 2018 (suppl; abstr 6069)
DOI
10.1200/JCO.2018.36.15_suppl.6069
Abstract #
6069
Poster Bd #
57
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.
First Author: Thiago Bueno Oliveira Sr.
Poster
2020 ASCO Virtual Scientific Program
A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).
First Author: Markus Hecht
Poster
2018 ASCO Annual Meeting
A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.
First Author: Xu Shan Sun
Poster
2013 ASCO Annual Meeting
Radiotherapy (RT) potentiation with weekly (q1w) or standard every 3 weeks (q3w) cisplatin chemotherapy (CT) for locally advanced head and neck squamous cell carcinoma (HNSCC).
First Author: Yann Molin